Allianz Biosciences Pvt Ltd - Leading Probiotic Manufacturer in India
Allianz Biosciences Pvt Ltd (ABPL) is a pioneer in probiotic research and manufacturing in India, with a state-of-the-art GMP-certified facility in Pondicherry. Established as a dedicated probiotic contract research and manufacturing organization (CRO & CMO), ABPL has positioned itself as a global leader in gut health, women's health, and immunity-boosting formulations.
Core Business & Expertise
ABPL specializes in developing, manufacturing, and exporting high-quality probiotic formulations that cater to multiple therapeutic areas, including gastrointestinal health, immunity, and women's health. The company integrates cutting-edge microbiome research with advanced fermentation technologies to deliver clinically validated probiotic products.
- State-of-the-Art Facility: GMP-certified and fully dedicated to probiotics.
- Regulatory Approvals: WHO-GMP, US-FDA registered facility.
- Global Reach: Supplies to over 20 countries, including the USA, Europe, and Asia.
- Contract Manufacturing (CMO) & Private Labeling: Partnering with global pharmaceutical and nutraceutical brands.
Product Portfolio
1. Gastrointestinal Health - Pre & Probiotics
- Bacillus Clausii
- Bifilac Activ (Combination of beneficial bacteria for gut health)
- Bifilac Capsules
- Bifilac Dry Syrup
- Bifilac GG (Lactobacillus rhamnosus GG)
- Vibact DS Capsules
- Unobiotics Duo (Multispecies probiotic blend)
- Rescunate (For diarrhea management)
- Colonise Forte (Synbiotic combination)
2. Women's Health
- Femflora (Designed for vaginal & gut microbiota balance)
3. Specialized Probiotic Formulations
- Bifilac Lozenge (Oral probiotics)
- Lipimod (Probiotics for metabolic health)
- Florasante (Probiotic with anti-inflammatory benefits)
ABPL's products are distributed under various brand names across global pharmaceutical markets.
Key Strengths & Differentiators
1. Probiotic Research & Innovation
ABPL’s in-house R&D team collaborates with leading universities and research institutes to develop clinically proven probiotic strains for multiple therapeutic applications. The company invests heavily in next-generation probiotic formulations, focusing on:
- Spore-forming probiotics for enhanced shelf stability.
- Multi-strain formulations tailored to specific health needs.
- Postbiotic formulations to boost gut immunity.
2. Certifications & Quality Compliance
ABPL’s GMP-certified facility adheres to the highest quality standards, ensuring the production of safe and effective probiotic formulations. Key certifications include:
- WHO-GMP
- ISO 22000:2018
- HACCP Certified
- US-FDA Registered
- FSSAI Approved
The company follows stringent quality control protocols across the entire probiotic production process, including strain selection, fermentation, freeze-drying, and packaging.
3. Global Market Presence & Exports
ABPL is a leading probiotic exporter, supplying over 20 countries, including:
- North America (USA, Canada)
- Europe (UK, Germany, Italy, France)
- Asia-Pacific (Japan, Australia, South Korea)
- Middle East & Africa
Export Statistics
- Over 10 million probiotic sachets and capsules exported annually.
- Strategic partnerships with leading pharma and nutraceutical brands in the global market.
Financial & Market Insights
- Annual Revenue (2023): Estimated at ₹150-200 crore (~$18-24 million).
- Production Capacity: Over 1 billion probiotic doses per year.
- R&D Investment: 12% of annual revenue dedicated to clinical trials & new product development.
- Key Customers: Leading pharma, nutraceutical, and hospital chains across the globe.
Customer Trust & Testimonials
ABPL’s probiotic formulations are clinically backed and trusted by gastroenterologists, pediatricians, and healthcare professionals worldwide. Some key testimonials:
- “Bifilac is one of the most reliable probiotic formulations we prescribe to our patients for gut health management.” – Dr. Ramesh Kumar, Gastroenterologist
- “Allianz Biosciences has been a trusted partner in probiotic formulations, ensuring high-quality strains that meet global standards.” – John Peterson, International Nutraceutical Distributor
Recent Achievements & Recognition
- Awarded "Best Probiotic Manufacturer" in 2023 by the Indian Pharmaceutical Association.
- Successfully launched Bifilac GG 10bn, an advanced high-potency probiotic formulation for IBS and gut disorders.
- Partnered with top research institutes for developing next-gen postbiotic formulations.
Future Roadmap
ABPL aims to expand its R&D capabilities and global footprint through:
- Introduction of next-gen probiotic strains with clinical efficacy.
- Expansion into US and European nutraceutical markets.
- Strategic collaborations with global pharma and biotech firms.
- Increased investment in microbiome-based therapies.
Conclusion
Allianz Biosciences Pvt Ltd stands as a leader in probiotic innovation and manufacturing, with a proven track record of delivering clinically validated, high-quality probiotic formulations to global markets. With strong R&D, cutting-edge manufacturing, and regulatory expertise, ABPL continues to drive probiotic advancements for better health worldwide.
